|

Pertuzumab Clinical Trials

35 actively recruiting trials across 8 locations

Also known as: 2C4, 2C4 Antibody, Anti-(Human V (Receptor)) (Human-Mouse Monoclonal 2C4 Heavy Chain), Disulfide with Human-Mouse Monoclonal 2C4 Kappa-Chain, HS627, Immunoglobulin G1, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, PErjeta, Perjeta, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, RO4368451, rhuMAb2C4

Other25 trials

A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
Phase 3
A Study for the Adjuvant Treatment of Breast Cancer
Phase 4
A Study for the Neoadjuvant Treatment of Breast Cancer
Phase 4
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
Phase 2/3
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Phase 2
Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
Phase 2
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Phase 2/3
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Phase 3
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
Phase 3
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Phase 3
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Phase 3
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Phase 2
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
Phase 1
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
Phase 2
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Phase 2
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Phase 2
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Phase 2
Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
Phase 2
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
Phase 3
The Sagittarius Trial
Phase 3
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
Phase 2
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
Phase 2
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
Phase 2
ctDNA in HER2+ EBC Neoadjuvant Treatment
Phase 2

Tampa, Florida2 trials

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Moffitt Cancer Center

Phase 1/2
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Moffitt Cancer Center

Phase 2

Boston, Massachusetts2 trials

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Dana-Farber Cancer Institute ( Site 0050)

Phase 1/2
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2

Phoenix, Arizona1 trial

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Cancer Center at Saint Joseph's

Phase 3

Long Beach, California1 trial

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Oncology Institute

Phase 2

Los Angeles, California1 trial

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 1/2

Chicago, Illinois1 trial

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

University of Illinois

Phase 2

Houston, Texas1 trial

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Harris Health System - Smith Clinic

Phase 2

Seattle, Washington1 trial

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.